Brought to you by
ECR 2019 / C-2567
Using ASL-perfusion to detection of residual glioblastoma tissue after surgical treatment
Congress: ECR 2019
Poster No.: C-2567
Type: Scientific Exhibit
Keywords: Tissue characterisation, Haemodynamics / Flow dynamics, Diagnostic procedure, Computer Applications-Detection, diagnosis, MR-Diffusion/Perfusion, MR, Oncology, Neuroradiology brain, Head and neck, Neoplasia
Authors: M. Bunak1, M. Vishnyakova1, G. Chermenskiy2; 1Moscow/RU, 2Москва/RU
DOI:10.26044/ecr2019/C-2567

Aims and objectives

MRI control in patients after surgical treatment of glioblastoma is an important neuroimaging method, both for assessing the volume of performed surgery and for detecting residual tumor tissue. Glioblastoma growth is often accompanied by impaired blood-brain barrier due to its infiltrative growth and is characterized by elevated hemodynamic parameters (CBV, CBF, MTT), associated with pronounced tumor angiogenesis (1,2,3). However, in the area of surgical intervention, the destruction of the blood-brain barrier is also noted. In this way the accumulation of a contrast agent in both cases makes it difficult to differentiate the residual tumor tissue against the background of postoperative changes in the brain (4). 

 

One of the approaches to visualization of residual glioblastoma tissue is perfusion CT and MRI studies (5). The method of ASL perfusion allows quantifying cerebral blood flow rate (CBF) in absolute terms (ml/100g per minute of brain tissue) without introducing a contrast agent by pseudo-continuous labeling of arterial hydrogen protons arterial blood (pcASL) feeding the brain (6,7). In this study we examine the efficiency of ASL perfusion as a method for assessing hemodynamics and identifying residual tumor tissue after surgical treatment of glioblastoma.

 

POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
SHARE THIS POSTER
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more